X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rosuvastatin calcium (1229) 1229
humans (1179) 1179
science & technology (1113) 1113
life sciences & biomedicine (1095) 1095
fluorobenzenes - therapeutic use (1065) 1065
sulfonamides - therapeutic use (974) 974
pyrimidines - therapeutic use (967) 967
male (908) 908
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (849) 849
female (724) 724
middle aged (578) 578
rosuvastatin (473) 473
aged (447) 447
cardiovascular system & cardiology (391) 391
cardiac & cardiovascular systems (347) 347
pharmacology & pharmacy (340) 340
treatment outcome (333) 333
statins (330) 330
animals (322) 322
fluorobenzenes - pharmacology (322) 322
cholesterol, ldl - blood (312) 312
adult (276) 276
fluorobenzenes - administration & dosage (242) 242
sulfonamides - pharmacology (229) 229
pyrimidines - pharmacology (226) 226
fluorobenzenes - adverse effects (215) 215
atorvastatin calcium (214) 214
pyrimidines - administration & dosage (208) 208
sulfonamides - administration & dosage (207) 207
risk factors (204) 204
sulfonamides - adverse effects (202) 202
pyrimidines - adverse effects (201) 201
hypercholesterolemia - drug therapy (200) 200
cholesterol (199) 199
general & internal medicine (196) 196
heptanoic acids - therapeutic use (196) 196
pyrroles - therapeutic use (196) 196
cardiovascular diseases - prevention & control (193) 193
medicine, general & internal (191) 191
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (188) 188
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (177) 177
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (176) 176
dose-response relationship, drug (174) 174
rats (153) 153
abridged index medicus (151) 151
cardiovascular (151) 151
anticholesteremic agents - therapeutic use (149) 149
double-blind method (147) 147
antilipemic agents (131) 131
randomized controlled trials as topic (128) 128
simvastatin - therapeutic use (126) 126
c-reactive protein - metabolism (125) 125
lipids (122) 122
time factors (122) 122
atherosclerosis (117) 117
drug therapy, combination (117) 117
cardiovascular disease (116) 116
drug therapy (116) 116
prospective studies (111) 111
fluorobenzenes - pharmacokinetics (107) 107
cholesterol, hdl - blood (105) 105
biomarkers - blood (104) 104
peripheral vascular disease (103) 103
lipids - blood (100) 100
analysis (99) 99
aged, 80 and over (98) 98
dyslipidemias - drug therapy (98) 98
research (98) 98
mice (97) 97
atorvastatin (96) 96
cholesterol - blood (95) 95
hypercholesterolemia - blood (94) 94
statin (92) 92
triglycerides - blood (90) 90
clinical trials as topic (87) 87
hypercholesterolemia (83) 83
hyperlipidemias - drug therapy (82) 82
dosage and administration (81) 81
sulfonamides - pharmacokinetics (81) 81
care and treatment (80) 80
neurosciences & neurology (80) 80
pyrimidines - pharmacokinetics (80) 80
low density lipoproteins (79) 79
internal medicine (77) 77
drug interactions (76) 76
follow-up studies (76) 76
neurosciences (74) 74
medicine, research & experimental (72) 72
rats, sprague-dawley (72) 72
research & experimental medicine (72) 72
cholesterol, ldl - drug effects (71) 71
pyrimidines (70) 70
disease models, animal (69) 69
heart failure - drug therapy (68) 68
pravastatin - therapeutic use (68) 68
sulfonamides (68) 68
c-reactive protein (66) 66
c-reactive protein - analysis (64) 64
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (64) 64
clinical trials (63) 63
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1377) 1377
Russian (24) 24
German (23) 23
Italian (15) 15
Chinese (9) 9
Spanish (8) 8
French (7) 7
Swedish (7) 7
Dutch (5) 5
Japanese (5) 5
Portuguese (4) 4
Hungarian (3) 3
Turkish (3) 3
Ukrainian (3) 3
Czech (1) 1
Norwegian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The American heart journal, ISSN 0002-8703, 11/2014, Volume 168, Issue 5, pp. 682 - 689.e1
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 22, pp. 2078 - 2087
In this trial, intravascular ultrasonography was used to compare the effects of atorvastatin versus rosuvastatin on regression of coronary atherosclerosis.... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Coronary Vessels - diagnostic imaging | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Ultrasonography, Interventional | Male | Heptanoic Acids - adverse effects | Coronary Artery Disease - pathology | Pyrroles - adverse effects | Cholesterol, LDL - blood | Female | Pyrroles - therapeutic use | Coronary Vessels - pathology | Double-Blind Method | Rosuvastatin Calcium | Coronary Artery Disease - drug therapy | Anticholesteremic Agents - adverse effects | Disease Progression | Atorvastatin Calcium | Coronary Artery Disease - diagnostic imaging | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Cholesterol, HDL - blood | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Fluorobenzenes - therapeutic use | Drugs | Rosuvastatin | Dosage and administration | Product/Service Evaluations | Drug therapy | Atherosclerosis | Lipoproteins (low density) | Clinical trials | Cardiovascular disease | Patients | Cholesterol | Studies | Side effects | Ultrasonic imaging | Arteriosclerosis | Atorvastatin | Heart diseases | Lipoproteins (high density) | Ultrasound | Statins
Journal Article
European heart journal, ISSN 0195-668X, 09/2012, Volume 33, Issue 17, pp. 2151 - 2162
Aims CYP3A4-metabolized statins can influence the pharmacodynamic effect of clopidogrel. We sought to assess the impact of switching to a... 
Atorvastatin | Clopidogrel | Platelet | Non-CYP3A4-metabolized statin | High platelet reactivity | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Prospective Studies | Ticlopidine - therapeutic use | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Cytochrome P-450 CYP3A - physiology | Male | Pyrimidines - metabolism | Fluorobenzenes - pharmacology | Cytochrome P-450 CYP3A - genetics | Platelet Aggregation Inhibitors - pharmacology | Female | Aspirin - therapeutic use | Platelet Aggregation - drug effects | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Fluorobenzenes - metabolism | Pravastatin - metabolism | Rosuvastatin Calcium | Genotype | Coronary Artery Disease - drug therapy | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Ticlopidine - analogs & derivatives | Adenosine Diphosphate - pharmacology | Pyrroles - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Sulfonamides - metabolism | Drug Substitution | Fluorobenzenes - therapeutic use | Percutaneous Coronary Intervention
Journal Article
Pharmacological research, ISSN 1043-6618, 09/2011, Volume 64, Issue 3, pp. 180 - 186
Statins, long known to be beneficial in conditions where dyslipidemia occurs by lowering serum cholesterol levels, also have been proposed for use in neurodegenerative conditions, including Alzheimer disease... 
Alzheimer disease | Pleiotropic functions | Statins | Statins as Janus molecules | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Fatty Acids, Monounsaturated - pharmacology | Lovastatin - pharmacology | Heptanoic Acids - therapeutic use | Humans | Heptanoic Acids - adverse effects | Neurodegenerative Diseases - drug therapy | Quinolines - pharmacology | Fluorobenzenes - pharmacology | Fatty Acids, Monounsaturated - therapeutic use | Fatty Acids, Monounsaturated - adverse effects | Pyrroles - adverse effects | Indoles - pharmacology | Pyrroles - therapeutic use | Heptanoic Acids - pharmacology | Lovastatin - therapeutic use | Lovastatin - adverse effects | Alzheimer Disease - drug therapy | Rosuvastatin Calcium | Pyrimidines - pharmacology | Cholesterol - metabolism | Sulfonamides - pharmacology | Atorvastatin Calcium | Pyrroles - pharmacology | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Indoles - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Indoles - therapeutic use | Fluorobenzenes - adverse effects | Quinolines - therapeutic use | Fluorobenzenes - therapeutic use | Quinolines - adverse effects | Alzheimer's disease | Neuroprotection | Neurotoxicity | Neurodegenerative diseases | statins | Dyslipidemia | Clinical trials | Age | Cholesterol | Index Medicus
Journal Article
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 2015, Volume 131, Issue 17, pp. 1486 - 1494
Background Our aim was to describe the incidence and predictors of stroke in patients who have heart failure without atrial fibrillation (AF). Methods and... 
Heart failure | Stroke | Sinus rhythm | Atrial fibrillation | Risk factors | Ventricular ejection fraction | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Follow-Up Studies | Humans | Middle Aged | Male | Diabetes Mellitus, Type 1 - complications | Peptide Fragments - blood | Aged, 80 and over | Adult | Female | Stroke - epidemiology | Natriuretic Peptide, Brain - blood | Benzimidazoles - therapeutic use | Heart Failure - complications | Stroke - prevention & control | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Rosuvastatin Calcium | Biomarkers - blood | Heart Failure - drug therapy | Randomized Controlled Trials as Topic | Stroke Volume | Cardiovascular Agents - therapeutic use | Stroke - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Atrial Fibrillation - etiology | Fatty Acids, Omega-3 - therapeutic use | Tetrazoles - therapeutic use | Aged | Fluorobenzenes - therapeutic use | Fatty Acids | Peptide Fragments/ blood | Omega-3/ therapeutic use | Tetrazoles/therapeutic use | Sulfonamides/ therapeutic use | Kardiologi | 80 and over | atrial fibrillation | Biological Markers/blood | sinus rhythm | Natriuretic Peptide | Pyrimidines/ therapeutic use | heart failure | Cardiovascular Agents/therapeutic use | Stroke/epidemiology/ etiology/prevention & control | Benzimidazoles/therapeutic use | Diabetes Mellitus | stroke | Type 1/complications | Brain/ blood | Cardiac and Cardiovascular Systems | Atrial Fibrillation/etiology | Fluorobenzenes/ therapeutic use | ventricular ejection fraction | Hydroxymethylglutaryl-CoA Reductase Inhibitors/ therapeutic use | Heart Failure/complications/ drug therapy
Journal Article
PloS one, ISSN 1932-6203, 03/2012, Volume 7, Issue 3, p. e33559
Journal Article
Journal Article